| QUIZARTINIB DIHYDROCHLORIDE | None | ||
| 17.7MG, 26.5MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| VANFLYTA is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. | |||
|
Yes
| |||
| VANFLYTA | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||
| ***************** ********* *** *** ********* ** ******* | ******* ** ************* *-(*-****-*****-********-*-**)-*′-{*-[*-(*-*********-*-**-******)*******[*,*-*][*,*]************-*-**]******}**** ** ***** ************* ******* | ****** ** ***** ***************** ********* *** *** ********* ** ******* | ******* ** ********* ***** *********** ******* | ***************** ********* *** *** ********* ** ******* | ******* ** ********* ***** *********** ******* | ******* ** ******** ************* ******** | ***** ***** ********** *-(*-****-*****-********-*-**)-*′-{*-[*-(*-*********-*-**-******)*******[*,*-*][*,*]************-*-**]******}****, ************ *******, *** **** ********* | ******* ** ******** ************* ******** | ***** ***** ********** *-(*-****-*****-********-*-**)-*′-{*-[*-(*-*********-*-**-******)*******[*,*-*][*,*]************-*-**]******}****, ************ *******, *** **** ********* | ****** ********** ********* **** ************ |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|